Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
PKPD: PAST, PRESENT AND
FUTUREApplied to antibiotics - Prof. Dr. An Vermeulen - 23 Nov 2017
DEPARTMENT OF BIOANALYSIS
LABORATORY OF MEDICAL BIOCHEMISTRY AND CLINICAL ANALYSIS
2
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0
Efficacy
Toxicity
Dose (exposure)
Effect
DOSE SELECTION MADE EASY
3
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0
Dose (exposure)
Effect
IN REALITY …
4
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0 Efficacy
Toxicity
Dose (exposure)
Effect
… KNOWLEDGE IS IMPRECISE
Uncertainty
5
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0 Efficacy
Toxicity
Dose (exposure)
Effect
ALSO, ALL PATIENTS ARE DIFFERENT
Inherent
Biological
Variability
6
− We try to establish relationships between exposure (mostly plasma
concentrations) and effects
− In a way, if we focus on PK, it is because we believe it is a biomarker for
effects, and that understanding the PK profile helps to understand the PD
(effects) profile
− Most of the times, we can not measure the concentrations at the effect site,
and we sample plasma concentrations instead (easy matrix to sample and
to measure concentrations in)
− The relationship between plasma and effect site concentrations is then
again linked mathematically
− Once a model is developed, it allows simulations of scenarios we have
not studied/for which we do not have information
− Time points w/o sampling
− Additional doses/dose regimen
− Repeated dosing (using single dose data)
− At population & individual level
− For different covariate subgroups (pediatrics, CrCL, BWT, ..)
PKPD MODELING
7
PKPD MODEL APPLICATIONS
• Conceptualization and quantification
• In vitro In vivo extrapolation
• Species scaling
• Clinical trial design
• Design of new dosage forms
• Comparative efficacy/toxicity
• Patent enhancement
• Labeling advice
8
PHARMACOKINETICS
9
PHARMACOKINETICSPharmacokinetics is the study and mathematical characterization of the time
course of drug absorption, distribution, metabolism, and excretion (ADME)
processes that determine the time-course of drug action.
Adapted from Atkinson, Principles of Clinical Pharmacology (2001)
PRESCRIBED DOSE
DRUG PRODUCT
ABSORPTION
PLASMA
FREEPROTEINBOUND
ELIMINATION
METABOLISM RENALEXCRETION
MOST TISSUES
NONSPECIFIC
BINDING
BIOPHASE
RECEPTORBINDING
DISTRIBUTION
EFFECT
BIOPHARMACEUTICS COMPLIANCE
10
11
NONCOMPARTMENTAL ANALYSIS
12
NONCOMPARTMENTAL ANALYSIS
PRIMARY PHARMACOKINETIC PROPERTIES
van de Waterbeemd and Gifford. Nature Rev Drug Disc. 2:192-204 (2003)13
COMPARTMENTAL ANALYSIS
14
COMPARTMENTAL ANALYSIS
0 5 10 15 20
0.1
0.5
1.0
# 4 50001
Time, h
R2
091
30
, ng
/ml
15
16
THE ASPECT VARIABILITY
− Modelling is essentially similar at the population level !
− But ..− At the population level, the aspect variability comes into play
− In a population analysis, the focus is on
− estimating the magnitude of this variability
− trying to identify patient characteristics that can explain (part of) this variability
− dose-adjustments in subsets? LABELLING impact !
− dose-individualisation in individuals? (avoid TDM - therapeutic drug monitoring)
− So ..− Three levels of variability have to be considered:
− IIV or BSV: inter-individual or between-subject variability
− IOV: inter- or between-occasion variability
− Intra-subject, within-subject or residual (unexplained) variability16
THE ASPECT VARIABILITY
0 5 10 15 20
0.1
0.5
1.0
# 4 50001
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l0 5 10 15 20
0.5
1.0
# 4 50002
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l0 5 10 15 20
0.5
1.0
# 4 50003
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l0 5 10 15 20
0.2
0.3
0.5
# 4 50004
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.5
1.0
# 4 50005
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.5
1.0
# 4 50006
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.1
0.5
1.0
# 4 50007
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.2
0.4
0.7
# 4 50008
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.5
1.0
# 4 50009
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.5
1.0
# 4 50010
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
0 5 10 15 20
0.1
0.5
1.0
# 4 50011
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
Time, h
R2
09
13
0, n
g/m
l
17
− Nonlinear Mixed Effects Modelling (NONMEM)
− Mixed effects− Fixed effects ()
− Random effects (, )
− Fixed effects− Estimate mean PK(PD) parameters in the population (= typical values,
central tendency, population average, ..)
− Identify factors that influence the PK (PD) parameters (demographics, lab values, PGx, smoking habits etc…)
− Random effects− Estimate unexplained variability
=> IIV, IOV and residual variability
POPULATION PK PRINCIPLES
18
PHARMACODYNAMICS
19
PK-PD RELATIONSHIPS: TYPE OF EFFECTS
Drug effect
Reversible
Irreversible
Direct
Indirect
20
REVERSIBLE EFFECTS – DIRECT CONCENTRATION-EFFECT MODELS
)(
)ln(
50
max
50
max
p
p
p
p
p
p
p
CEC
CEEffect
CEC
CEEffect
CEffect
CEffect
CEffect
Linear
Log-linear
Power
Emax
Sigmoid Emax
Effect directly
related to plasma
concentration
EC50/IC50 values: the potency of the drug
Emax/Imax values: the efficacy of the drug
γ : sigmoidicity factor 21
22
23
REVERSIBLE EFFECTS – INDIRECTMODELING A BIOPHASE
Segre, Il Pharmaco (1968)
Sheiner et al., CPT (1979)
eCpCeokdt
edC
eC50EC
eCmaxEE
24
25
REVERSIBLE EFFECTS – INDIRECT
26
Chemotherapeutic effects
Simple cell killing
Killing and regrowth
Cell cycle effects
Clinical therapy
Irreversible enzyme inhibition
Reactive drug metabolites
Simple drug toxicity
Carcinogenicity models
IRREVERSIBLE EFFECTS
27
SIMPLE CELL KILLING
ln SF = -k * D0/CL
J. Pharm. Sci. 60:892 (1971)
Drecker functionN = R
28
SIMPLE CELL KILLING
Spleen cells
Osteosarcoma cells
Cyclophosphamide - mice
29
CELL KILLING – CELL GROWTH
30
CELL KILLING – CELL GROWTH
ANTIBACTERIAL EFFECTS
31
32
PKPD: PAST, PRESENT AND FUTURE …
33
MIC
34
MIC
kg = ks
35
SUMMARY PK MEASURES
36
ANTIBACTERIAL EFFECTS
37
ANTIBACTERIAL EFFECTS
38
Antibiotics
Thigh Lung
39
MIC DISTRIBUTION
40
TARGET ATTAINMENT
41
TARGET ATTAINMENT
42
CLINICAL AND MICROBIOLOGICAL CURE
43
CLINICAL CURE
44
CLINICAL BREAKPOINTPKPD BREAKPOINT
45
MODELING TIME COURSE OF ANTIBIOTIC EFFECT
• Better to model time course
of bacterial growth & killing
• Differentiate between the
system (bacteria) and drug
effects
• Can address resistance development
• .. and the effects of the host’s immune
system
=> Use all available data: in vitro, animal, clinical
46
SYSTEMS PHARMACOLOGY: PBPK
47
… COMBINED WITH PD MODEL AT INFECTION SITE
48
… ALLOWS TO DERIVE THE TISSUES WITH HIGHEST EFFECT
An VermeulenPharmacokinetics and Pharmacodynamics/PBPK/Pharmacometrics
DEPARTMENT OF BIOANALYSIS
T +32 9 264 81 12
M +32 474 55 08 65
www.ugent.be
Ghent University
@ugent
Ghent University